Skip to main content
Article thumbnail
Location of Repository

Is quantitative benefit–risk modelling of drugs desirable or possible?

By Lawrence D. Phillips, Barbara Fasolo, Nikolaos Zafiropoulos and Andrea Beyer

Abstract

Preliminary research results with drug regulators in several European Agencies show that quantitative models developed with groups of assessors and specialists can integrate scientific data with expert value judgements, thereby extending the capabilities of regulators, and stimulating new insights about key trade-offs. As a result, the rationale for the benefit-risk balance becomes more transparent, communicable and consistent

Topics: RS Pharmacy and materia medica
Publisher: Elsevier
Year: 2011
DOI identifier: 10.1016/j.ddtec.2011.03.001
OAI identifier: oai:eprints.lse.ac.uk:39733
Provided by: LSE Research Online
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.journals.elsevier.c... (external link)
  • http://eprints.lse.ac.uk/39733... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.